A phase 2 clinical trial of the pharmacological chaperone AT2101 for the treatment of Gaucher disease

被引：0
|
作者：
Weinreb, N. [1 ]
Schneider, E. [2 ]
Dinh, Q. [2 ]
Duke, C. [2 ]
Insinga, A. F. [2 ]
Scott, K. [2 ]
Do, H. [2 ]
Wustman, B. [2 ]
Palling, D. [2 ]
Lockhart, D. J. [2 ]
机构：
[1] Res Fdn LSDs Inc, Coral Springs, FL USA
[2] Amicus Therapeut Inc, Cranbury, NJ USA
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
427P
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [21] Interest of the pharmacological chaperone migalastat in the treatment of Fabry disease
    Noel, Esther
    Mourot-Cottet, Rachel
    Andres, Emmanuel
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S106 - S106
  • [22] The pharmacological chaperone AT1001 and treatment of Fabry disease
    Khanna, Richie
    Benjamin, Elfrida R.
    Soska, Rebecca
    Lun, Yi
    Sitaraman, Sheela A.
    Palling, David J.
    Lockhart, David J.
    Valenzano, Kenneth J.
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S26 - S26
  • [23] Preliminary results of a phase 2 clinical trial of Genz-112638 in patients with type I Gaucher disease
    Lukina, E.
    Watman, N.
    Arreguin, E. A.
    Banikazemi, M.
    Iastrebner, M.
    Rosenbaum, H.
    Zimran, A.
    O'Brien, F.
    Smith, S. E.
    Puga, A. C.
    Peterschmitt, J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 114 - 114
  • [24] Preliminary study of the chaperone effect on mutated glucocerebrosidases as a treatment for Gaucher disease.
    Sanchez-Olle, G.
    Egido-Gabas, M.
    Duque, J.
    Casas, J.
    Chabas, A.
    Vilageliu, L.
    Grinberg, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 374 (04) : 344 - 345
  • [25] A Prematurely Halted, Randomized, Controlled Clinical Trial of Alendronate Treatment in Patients with Gaucher Disease
    Sun, Shumei S.
    BIOPHARMACEUTICAL APPLIED STATISTICS SYMPOSIUM, VOL 3: PHARMACEUTICAL APPLICATIONS, 2018, : 185 - 191
  • [26] Docking and SAR studies of calystegines: Binding orientation and influence on pharmacological chaperone effects for Gaucher's disease
    Kato, Atsushi
    Nakagome, Izumi
    Nakagawa, Shinpei
    Koike, Yuriko
    Nash, Robert J.
    Adachi, Isao
    Hirono, Shuichi
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (08) : 2435 - 2441
  • [27] Exploring the Use of Pharmacological Chaperone AT3375 Alone and in Combination with Recombinant human β-Glucosidase for Gaucher Disease
    Khanna, Richie
    Pellegrino, Lee
    Soska, Rebecca
    Lun, Yi
    Feng, Jessie
    Frascella, Michelle
    Ranes, Brian E.
    Guillen, Darlene
    Garcia, Anadina
    Flanagan, John J.
    Lockhart, David J.
    Clark, Sean W.
    Valenzano, Kenneth J.
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S40 - S40
  • [28] GENZ-112638, AN INVESTIGATIONAL ORAL THERAPY FOR GAUCHER DISEASE TYPE 1: PHASE 2 CLINICAL TRIAL RESULTS AFTER ONE YEAR OF TREATMENT
    Lukina, E.
    Watman, N.
    Arreguin, E.
    Banikazemi, M.
    Pastores, G.
    Iastrebner, M.
    Dragosky, M.
    Rosenbaum, H.
    Zimran, A.
    Kaper, M.
    Smith, S. E.
    Puga, A. C.
    Peterschmitt, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 41 - 41
  • [29] Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease
    Laigre, Eugenie
    Hazelard, Damien
    Casas, Josefina
    Serra-Vinardell, Jenny
    Michelakakis, Helen
    Mavridou, Irene
    Aerts, Johannes M. F. G.
    Delgado, Antonio
    Compain, Philippe
    CARBOHYDRATE RESEARCH, 2016, 429 : 98 - 104
  • [30] Improved pharmacological chaperones for the treatment of neuronopathic Gaucher and Parkinson's disease
    Clark, Sean
    Lee, Gary
    Boyd, Robert
    Sullivan, Sean
    Pellegrino, Lee
    Frascella, Michelle
    Khanna, Richie
    Brignol, Nastry
    Wustman, Brandon
    Rybczynski, Philip
    Benjamin, Elfrida
    Valenzano, Kenneth
    Lockhart, David J.
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (02) : S12 - S12
12345